Braidwell’s Arcus Biosciences RCUS Stock Holding History

Braidwell’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-802,100	Closed	-$11.9M	–	77
2024 Q4	$11.9M	Buy	+802,100	New	+$13.1M	0.35%	61

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Braidwell's RCUS Position: Q1 2025 in Review

Braidwell sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 802,100 shares — an estimated $11.9M sold.

Braidwell first reported a position in RCUS in Q4 2024 and held it in 1 quarter. The position peaked at $11.9M in Q4 2024. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

Braidwell reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
Braidwell sold 802,100 Arcus Biosciences shares in Q1 2025, an estimated $11.9M.
Braidwell first reported a position in Arcus Biosciences in Q4 2024 and held it in 1 quarter.
Braidwell's Arcus Biosciences position peaked at $11.9M in Q4 2024.
186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.